Published in Mycoses on May 10, 2011
Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol (2012) 2.82
Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis. J Clin Microbiol (2013) 0.90
Comparative evaluation of BD Phoenix and vitek 2 systems for species identification of common and uncommon pathogenic yeasts. J Clin Microbiol (2013) 0.84
Antifungal susceptibility testing: current role from the clinical laboratory perspective. Mediterr J Hematol Infect Dis (2014) 0.77
Metabolic coupling, ionic coupling and cell contacts. Nature (1972) 4.71
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 4.17
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant (2010) 3.46
Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother (1998) 3.09
Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis (1999) 2.96
Bacterial contamination of needles used for spinal and epidural anaesthesia. Br J Anaesth (1999) 2.69
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect (2014) 2.47
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother (2006) 2.31
Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis (1999) 2.28
Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett (1997) 2.15
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother (2013) 2.14
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother (2001) 2.13
Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost (2006) 2.08
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect (2014) 2.06
Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis (2007) 2.04
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (1998) 2.00
PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J Clin Pathol (2005) 1.89
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood (1996) 1.88
Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost (2008) 1.81
Acute severe spinal cord dysfunction in bacterial meningitis in adults: MRI findings suggest extensive myelitis. Arch Neurol (2001) 1.79
Changing epidemiology of systemic fungal infections. Clin Microbiol Infect (2008) 1.77
ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect (2014) 1.70
Species identification of Aspergillus, Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Microbiol Infect (2011) 1.69
New targets and delivery systems for antifungal therapy. Med Mycol (2000) 1.65
EUCAST technical note on anidulafungin. Clin Microbiol Infect (2011) 1.63
Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis (2015) 1.61
Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis (2010) 1.60
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother (1999) 1.60
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses (1999) 1.54
[Vancomycin resistant enterococci in Austria]. Wien Klin Wochenschr (1997) 1.51
Colour Doppler ultrasonography to detect pannus in knee joint synovitis. Clin Exp Rheumatol (2000) 1.51
Inflammatory mediators in bronchoalveolar lavage fluid and plasma in leukocytopenic patients with septic shock-induced acute respiratory distress syndrome. Crit Care Med (1998) 1.50
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect (2012) 1.48
Tap water colonization with Pseudomonas aeruginosa in a surgical intensive care unit (ICU) and relation to Pseudomonas infections of ICU patients. Infect Control Hosp Epidemiol (2001) 1.46
[Clinical research in orthopaedics--creation of a clinical trial unit in orthopaedics/trauma surgery]. Z Orthop Unfall (2010) 1.45
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect (2012) 1.41
The role of staging bronchoscopy in the preoperative assessment of a solitary pulmonary nodule. Chest (1993) 1.40
[62-year-old patient with chronic lymphatic leukaemia and persistent fever in chemotherapy induced bone marrow aplasia. Angioinvasive aspergillosis]. Dtsch Med Wochenschr (2011) 1.39
EUCAST technical note on voriconazole and Aspergillus spp. Clin Microbiol Infect (2013) 1.38
EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect (2012) 1.37
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect (2014) 1.36
Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother (2009) 1.31
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother (2012) 1.28
Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother (2010) 1.28
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother (2009) 1.24
Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect (2010) 1.21
Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother (2001) 1.20
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob Agents Chemother (2013) 1.20
O-antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections. Clin Diagn Lab Immunol (1997) 1.17
Chronic pulmonary aspergillosis. Mycoses (2013) 1.17
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents (2010) 1.15
Towards a medically approved technology for alginate-based microcapsules allowing long-term immunoisolated transplantation. J Mater Sci Mater Med (2005) 1.15
Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother (2014) 1.13
Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest (1990) 1.11
Persistence of excitation contraction coupling in "slow" muscle fibres after a treatment that destroys transverse tubules in "twitch" fibres. Nature (1968) 1.10
Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect (2013) 1.10
Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther (2011) 1.07
Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol (2003) 1.07
In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J Chemother (2009) 1.05
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother (2012) 1.02
Acute anterior myocardial infarction as first manifestation of acute myeloid leukemia. Ann Hematol (2001) 1.01
Molecular epidemiology of Candida isolates from AIDS patients showing different fluconazole resistance profiles. J Clin Microbiol (1995) 1.00
Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators. Eur J Clin Microbiol Infect Dis (2002) 1.00
Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis (2004) 0.99
Secretion of E,E-farnesol and biofilm formation in eight different Candida species. Antimicrob Agents Chemother (2008) 0.99
New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist (2000) 0.99
Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect (2013) 0.99
Improvement of detection of bacterial pathogens in normally sterile body sites with a focus on orthopedic samples by use of a commercial 16S rRNA broad-range PCR and sequence analysis. J Clin Microbiol (2012) 0.98
Surviving high-intensity field pulses: strategies for improving robustness and performance of electrotransfection and electrofusion. J Membr Biol (2005) 0.98
Pandemic 2009 influenza A(H1N1) virus infection coinciding with invasive pulmonary aspergillosis in neutropenic patients. Epidemiol Infect (2011) 0.98
Overview: non-fumigatus species of Aspergillus: perspectives on emerging pathogens in immunocompromised hosts. Curr Opin Investig Drugs (2001) 0.98
Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost (1996) 0.97
Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect (2009) 0.97